Results 141 to 150 of about 1,671,645 (312)
Outbreaks Associated with Fresh Produce: Incidence, Growth, and Survival of Pathogens in Fresh and Fresh‐Cut Produce [PDF]
L.J. Harris +6 more
openaire +1 more source
PUBLIC MARKETS AND THE DEVELOPMENT OF THE FRESH-PRODUCE INDUSTRY [PDF]
Agribusiness,
Brooker, John R. +5 more
core +1 more source
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon +13 more
wiley +1 more source
Sonochemical treatment of packaging materials for prolonging fresh produce shelf life. [PDF]
Abu Salha B, Perelshtein I, Gedanken A.
europepmc +1 more source
Fresh produce as a potential vector for bacterial human pathogens [PDF]
Hamilton +8 more
core +1 more source
Produce Sourcing and Transportation Cost Effects on Wholesale Fresh Fruit and Vegetable Prices [PDF]
Demand and Price Analysis,
Leibtag, Ephraim S., Roeger, Edward
core +1 more source
Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li +10 more
wiley +1 more source
Lignan-containing maple products inhibit Listeria monocytogenes biofilms on fresh produce. [PDF]
Elbakush AM, Fulano AM, Gomelsky M.
europepmc +1 more source
AN OVERVIEW OF KEY FOOD INDUSTRY DRIVERS: IMPLICATION FOR THE FRESH PRODUCE INDUSTRY [PDF]
Agribusiness,
Cook, Roberta L.
core +1 more source
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source

